/
AKTS
$30.11+$0.67 (+2.28%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$1.6B
55M shares
52-week range
$14.72 – $33.53
82% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
1.02%
Moderate
Price (6 mo)
Loading chart…
Change+$19.32
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $1.5M | $6.5M |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $1.5M | $6.5M |
| Gross margin | — | — | 100.0% | 100.0% |
| R&D | $14.3M | $25.9M | $41.0M | $67.5M |
| Operating income | −$19.8M | −$34.8M | −$52.0M | −$74.7M |
| EBITDA | −$17.5M | −$27.4M | −$42.4M | −$61.4M |
| Net income | −$17.9M | −$28.6M | −$44.0M | −$63.7M |
| Net margin | — | — | -2957.6% | -980.9% |
| EPS (diluted) | -0.51 | -0.82 | -1.26 | -1.19 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $18M | $-1.63 | $-2.09–$-1.13 | 5 |
| 2027 | $12M | $-2.18 | $-3.15–$-1.45 | 5 |
| 2028 | $2M | $-3.00 | $-6.51–$-0.47 | 1 |
| 2029 | $5M | $-3.52 | $-7.63–$-0.55 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$2.17
Price
$30.11
Implied downside
-93%
Aktis Oncology, Inc. Common stock
Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. The company has one operating and reportable segment focused on the research and development of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. The company generates revenue from Collaboration agreement.
www.aktisoncology.com- Employees
- 79
- IPO / List date
- Jan 9, 2026
- HQ
- BOSTON, MA
Held by traders on TradeandTell
No one on the platform currently holds AKTS.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in AKTS as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2015-04-24 | 1.094891-for-1 |
Recent trades on TradeandTell
No one on the platform has traded AKTS yet.
